Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Other Non-Current Liabilities (2019 - 2025)

Bioadaptives' Other Non-Current Liabilities history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.7 million for Q4 2025, up 65.09% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 65.09% YoY), and the annual figure for FY2025 was $1.7 million, up 65.09%.
  • Other Non-Current Liabilities for Q4 2025 was $1.7 million at Bioadaptives, up from $967406.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q4 2025 to a low of $120000.0 in Q3 2021.
  • The 5-year median for Other Non-Current Liabilities is $870973.5 (2021), against an average of $852470.8.
  • The sharpest move saw Other Non-Current Liabilities tumbled 84.02% in 2021, then soared 65.09% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $557042.0 in 2021, then increased by 23.3% to $686856.0 in 2022, then skyrocketed by 42.37% to $977872.0 in 2023, then rose by 7.71% to $1.1 million in 2024, then surged by 65.09% to $1.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.7 million, $967406.0, and $860636.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.